Literature DB >> 7535341

Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.

E Racila1, R H Scheuermann, L J Picker, E Yefenof, T Tucker, W Chang, R Marches, N E Street, E S Vitetta, J W Uhr.   

Abstract

Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge. In this report, we have investigated the immunological and cellular mechanisms underlying the induction of dormancy. BCL1 tumor cells were injected into SCID mice passively immunized with antibody against different epitopes on IgM or IgD with or without idiotype (Id)-immune T lymphocytes. Results indicate that antibody to IgM is sufficient to induce a state of dormancy. Antibodies against other cell surface molecules including IgD and CD44 (Pgp1) had no effect on tumor growth. Id-immune T cells by themselves also had no effect on tumor growth in SCID mice. However, simultaneous transfer of anti-Id and Id-immune T cells enhanced both the induction and duration of the dormant state. In vitro studies indicated that antibody to IgM induced apoptosis within several hours and cell cycle arrest by 24 h. Hyper cross-linking increased apoptosis. The Fc gamma RII receptor played little or no role in the negative signaling. Antibodies that did not negatively signal in vitro did not induce dormancy in vivo. The results suggest that anti-IgM plays a decisive role in inducing tumor dormancy to BCL1 by acting as an agonist of IgM-mediated signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535341      PMCID: PMC2191969          DOI: 10.1084/jem.181.4.1539

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  51 in total

1.  Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.

Authors:  M J Dyer; G Hale; F G Hayhoe; H Waldmann
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

2.  Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products.

Authors:  J P Jakway; W R Usinger; M R Gold; R I Mishell; A L DeFranco
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

3.  Configurations of a polymeric antigen adsorbed to a B-cell membrane.

Authors:  F W Wiegel; A S Perelson
Journal:  J Theor Biol       Date:  1981-02-07       Impact factor: 2.691

4.  Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis.

Authors:  N E Phillips; D C Parker
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

5.  Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis.

Authors:  R C Duke; R Chervenak; J J Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

6.  Induction of proliferation and differentiation of murine B cells bearing surface Ig lambda by rat monoclonal antibody to lambda chain.

Authors:  K Yagawa; E S Vitetta
Journal:  Hybridoma       Date:  1983

7.  Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).

Authors:  K Dorshkind; S B Pollack; M J Bosma; R A Phillips
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

8.  Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.

Authors:  A J George; A L Tutt; F K Stevenson
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

9.  Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells.

Authors:  D Herlyn; M Herlyn; Z Steplewski; H Koprowski
Journal:  Cell Immunol       Date:  1985-04-15       Impact factor: 4.868

10.  Lymphoma models for B cell activation and tolerance. III. Cell cycle dependence for negative signalling of WEHI-231 B lymphoma cells by anti-mu.

Authors:  D W Scott; D Livnat; C A Pennell; P Keng
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  16 in total

1.  Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo.

Authors:  C Knörr; C Amrehn; H Seeberger; A Rosenwald; S Stilgenbauer; G Ott; H K Müller Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells.

Authors:  H K Müller-Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 3.  Controversies in clinical cancer dormancy.

Authors:  Jonathan W Uhr; Klaus Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

4.  The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody.

Authors:  M Welschof; P Terness; S M Kipriyanov; D Stanescu; F Breitling; H Dörsam; S Dübel; M Little; G Opelz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

5.  Inverse correlation between IgG-antihinge region and antierythrocyte autoantibody in chronic benign and malignant cold agglutination.

Authors:  P Terness; M Kirschfink; D Navolan; L Moroder; F Siedler; D Drugarin; F Schneider; C Dufter; I Kohl; M Welschof; G Opelz; D Roelcke
Journal:  J Clin Immunol       Date:  1997-05       Impact factor: 8.317

6.  Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction.

Authors:  E Racila; R Hsueh; R Marches; T F Tucker; P H Krammer; R H Scheuermann; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.

Authors:  R Marches; R Hsueh; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

8.  The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement.

Authors:  Emilian Racila; Doina M Racila; Justine M Ritchie; Christiana Taylor; Christopher Dahle; George J Weiner
Journal:  Immunogenetics       Date:  2006-02-08       Impact factor: 2.846

Review 9.  Immunotherapy of cancer: targeting cancer during active disease or during dormancy?

Authors:  Syed Ammer Shah; Melika Zarei; Saeed H Manjili; Georgi Guruli; Xiang-Yang Wang; Masoud H Manjili
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

Review 10.  The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.

Authors:  Emma Risson; Ana Rita Nobre; Veronique Maguer-Satta; Julio A Aguirre-Ghiso
Journal:  Nat Cancer       Date:  2020-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.